These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 32086326)
21. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. Albers FC; Price RG; Smith SG; Yancey SW J Allergy Clin Immunol; 2017 Nov; 140(5):1464-1466.e4. PubMed ID: 28687231 [No Abstract] [Full Text] [Related]
22. Mepolizumab: A Review in Eosinophilic Asthma. Deeks ED BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938 [TBL] [Abstract][Full Text] [Related]
23. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. Kavanagh JE; d'Ancona G; Elstad M; Green L; Fernandes M; Thomson L; Roxas C; Dhariwal J; Nanzer AM; Kent BD; Jackson DJ Chest; 2020 Aug; 158(2):491-500. PubMed ID: 32275980 [TBL] [Abstract][Full Text] [Related]
24. Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis. Lugogo N; Liu MC; Pavord I; Mitchell PD; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Bel EH J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3506-3509.e3. PubMed ID: 34111572 [No Abstract] [Full Text] [Related]
25. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center's early clinical experience. Weir E; Paton J J Asthma; 2020 May; 57(5):521-524. PubMed ID: 30795693 [No Abstract] [Full Text] [Related]
26. May mepolizumab used in asthma correct subfertility? Ozden G; Pınar Deniz P Ann Med; 2021 Dec; 53(1):456-458. PubMed ID: 33739210 [TBL] [Abstract][Full Text] [Related]
27. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia. Sato H; Miyata Y; Inoue H; Tanaka A; Sagara H J Investig Allergol Clin Immunol; 2021 Oct; 31(5):459-460. PubMed ID: 33502319 [No Abstract] [Full Text] [Related]
28. Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma. Howarth P; Quirce S; Papi A; Israel E; Mallett S; Bates S; Yancey S; Albers FC; Kwon N Allergy; 2020 Aug; 75(8):2085-2088. PubMed ID: 32147844 [No Abstract] [Full Text] [Related]
29. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700 [No Abstract] [Full Text] [Related]
30. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Gupta A; Pouliquen I; Austin D; Price RG; Kempsford R; Steinfeld J; Bradford ES; Yancey SW Pediatr Pulmonol; 2019 Dec; 54(12):1957-1967. PubMed ID: 31502421 [TBL] [Abstract][Full Text] [Related]
31. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study. Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936 [TBL] [Abstract][Full Text] [Related]
33. Mepolizumab treatment in patients with severe eosinophilic asthma. Ortega HG; Liu MC; Pavord ID; Brusselle GG; FitzGerald JM; Chetta A; Humbert M; Katz LE; Keene ON; Yancey SW; Chanez P; N Engl J Med; 2014 Sep; 371(13):1198-207. PubMed ID: 25199059 [TBL] [Abstract][Full Text] [Related]
34. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852 [TBL] [Abstract][Full Text] [Related]
35. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781 [TBL] [Abstract][Full Text] [Related]
36. Mepolizumab prefilled syringe for the treatment of severe eosinophilic asthma: focus on the pediatric population. Revier MD; Geng B Expert Rev Respir Med; 2022 Aug; 16(8):857-865. PubMed ID: 35916083 [TBL] [Abstract][Full Text] [Related]